Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function

Completed

• Conditions: Cystic Fibrosis in Children

• Registration Number: NCT04138589
• Lead Sponsor: University Medical Center Groningen

Brief Summary

To obtain prospective real world data of the effect of lumacaftor/ivacaftor or tezacaftor/ ivacaftor on small airway disease in children aged 6-18 years with cystic fibrosis (CF) homozygous for F508del. The effect of the medication on small airway disease is evaluated by measurement of multiple breath washout (MBW) with its outcome parameter lung clearance index (LCI) and the Perth-Rotterdam Annotated Grid Morphometric Analysis for CF (PRAGMA-CF) cpmputed tomography (CT) score. In addition the relation between changes in LCI and PRAGMA-CF score is evaluated.

Detailed Description

Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor or tezacaftor/ ivacaftor .

To collect these data and to assist in clinical decisions regarding initiation and continuation of lumacaftor/ivacaftor or tezacaftor/ ivacaftor, the investigators of the CF center (Beatrix Children's Hospital, University Medical Center Groningen (UMCG), the Netherlands) developed an extensive protocol of testing before children aged 6-18 years start therapy and during the first year after start.

The protocol includes the following tests: growth parameters, sweat test, lung function testing (spirometry, MBW, body plethysmography), blood test panel (AST, ALT, alkalic phosphatase (AF), total and direct bilirubin, LDH), fecal elastase, high resolution (HR)CT and CF quality of life questionnaires. These tests are repeated at regular intervals.

Multi-center observational study. Duration 12 months after the start of lumacaftor/ ivacaftor or tezacaftor/ ivacaftor .

Study Timeline

• Study Start: 2017-11-01
• Study First Submitted: 2019-09-18
• Study First Submitted QC: 2019-10-23
• Study First Posted: 2019-10-24
• Primary Completion: 2022-07-19
• Study Completion: 2022-07-19
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-28
• Last Update Posted: 2023-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Children aged 6-18 years
• CF, Homozygote F508del confirmed by DNA analysis
• Considered for start of lumacaftor/ ivacaftor or tezacaftor/ivacaftor

Exclusion Criteria

• • Unable to perform acceptable, repeatable lung function tests

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in lung clearance index	12 months	Change between t=0 and t=12

Secondary Outcome Measures

Name	Time	Method
Change in PRAGMA-CF score	12 months	Change between t=0 and t=12

Trial Locations

Locations (2)

Children's Hospital Marien Hospital Wesel; 🇩🇪 Düsseldorf, Germany

Beatrix Children's Hospital, University Medical Center Groningen; 🇳🇱 Groningen, Netherlands